Department of Biotechnology, Government of India
The government department that funds India's life-science institutes and, through BIRAC, the start-ups behind the country's indigenous CAR-T therapies and HPV vaccine.
Overview
The Department of Biotechnology was created in 1986 under the Ministry of Science and Technology. It runs autonomous institutes including the National Institute of Immunology (Delhi), the National Centre for Cell Science (Pune), the Institute for Stem Cell Science and Regenerative Medicine (Bengaluru), the Translational Health Science and Technology Institute (Faridabad), the Rajiv Gandhi Centre for Biotechnology (Thiruvananthapuram) and the Institute of Life Sciences (Bhubaneswar), and funds industry through the Biotechnology Industry Research Assistance Council (BIRAC), a public sector undertaking that supports biotech commercialisation.
For cancer, DBT and BIRAC grants sit behind much of the indigenous pipeline: the IIT Bombay and Tata Memorial CAR-T programme that became NexCAR19, academic cell therapy and gene therapy at inStem and CMC Vellore, and the development and rollout of the Serum Institute's quadrivalent HPV vaccine.
- Autonomous life-science institutes
- BIRAC start-up and translational grants
- Cell and gene therapy programmes
- Vaccine development support
Pages like this
not linked directly; found by shared links- PersonRahul Purwar
Shares Indian Institute of Technology Bombay, Point-of-care and decentralised cell manufacturing, ImmunoACT, Manufacturing cost and time for living and radioactive medicines.
- ProductTalicabtagene autoleucel
Shares Indian Institute of Technology Bombay, Point-of-care and decentralised cell manufacturing, ImmunoACT, Manufacturing cost and time for living and radioactive medicines.
- Key paperTalicabtagene autoleucel for relapsed or refractory B-cell malignancies: an open-label, multicentre, phase 1/2 study
Shares Indian Institute of Technology Bombay, ImmunoACT, Manufacturing cost and time for living and radioactive medicines, CAR-T cell therapy.
- IdeaPublic cell-therapy foundries at cancer centres for academics and start-ups
Shares The valley of death between lab and product, Manufacturing cost and time for living and radioactive medicines, CAR-T cell therapy.
- TrialTalicabtagene autoleucel (NexCAR19) phase 1/2
Shares Indian Institute of Technology Bombay, ImmunoACT, Manufacturing cost and time for living and radioactive medicines, CAR-T cell therapy.
- InstitutionAdvanced Centre for Treatment, Research and Education in Cancer
Shares Indian Institute of Technology Bombay, Point-of-care and decentralised cell manufacturing, ImmunoACT, CAR-T cell therapy.
- CompanyImmuneel Therapeutics
Shares Point-of-care and decentralised cell manufacturing, Manufacturing cost and time for living and radioactive medicines, CAR-T cell therapy.
- IdeaShared modular GMP facilities for academic personalised vaccines and cell products
Shares The valley of death between lab and product, Manufacturing cost and time for living and radioactive medicines, CAR-T cell therapy.